Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?
Bewersdorf J, Stone R, Tallman M, Stahl M. Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML? Leukemia & Lymphoma 2021, 62: 3318-3319. PMID: 34587866, DOI: 10.1080/10428194.2021.1986220.Peer-Reviewed Original Research